Autopsy report · NCT02541903

Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“poor overall accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 4 years 6 months before it stopped.
8 participants enrolled.
Results were posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: University of Alabama at Birmingham
Sponsor type: University, hospital or other
Conditions: Penile Squamous Cell Carcinoma (PSCC)
Interventions: Gilotrif
Participants: 8
Sites: 3
Countries: United States

Trials that died the same way

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
“poor accrual” (93% match in meaning)

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.